Amlodipine Cost in Arizona 2026: Cash Pay, Insurance, Medicaid, and Compounding

What Does Amlodipine Actually Cost in Arizona Right Now?

Generic amlodipine is one of the least expensive prescription drugs available in Arizona. The average cash-pay price at retail pharmacies across the state runs about $8 per month for a 30-day supply of 5 mg tablets in 2026. Prices vary by pharmacy chain, zip code, and coupon platform, but no Arizona resident should be paying close to the Pfizer brand (Norvasc) list price of roughly $80 per month without first exploring generics and discount programs.

At major chains across the Phoenix metro, Tucson, and Flagstaff, GoodRx-type coupons routinely bring the cash price to $4, $6 per month for 30 tablets. Walmart's $4 generic program covers amlodipine in most Arizona store locations, making it one of the cheapest ways to fill a 30-day supply without insurance. Costco and Sam's Club pharmacies in Arizona consistently list 30-count amlodipine at $5, $7 with their membership pharmacy pricing.

The FDA-approved amlodipine label confirms that the drug is indicated for hypertension and chronic stable or vasospastic angina and is available as 2.5 mg, 5 mg, and 10 mg oral tablets [1]. Because FDA exclusivity on the original Pfizer compound expired years ago, multiple generic manufacturers compete in the Arizona market, which keeps cash prices low. The American Heart Association notes that calcium channel blockers, including amlodipine, are first-line antihypertensive agents for many patients, supporting the drug's extremely high prescription volume and resulting price competition [2].

Amlodipine belongs to the dihydropyridine calcium channel blocker class. It works by blocking L-type calcium channels in vascular smooth muscle, reducing peripheral vascular resistance and lowering blood pressure over a 24-hour dosing window [3]. That long half-life (30 to 50 hours) makes once-daily dosing effective and reduces the clinical impact of a missed dose, which the FDA prescribing information documents in detail [1].

Arizona Medicaid (AHCCCS): Does It Cover Amlodipine?

AHCCCS does not list amlodipine on all managed care plan preferred drug lists, which surprises many patients given its low cost. Coverage depends on which AHCCCS-contracted managed care organization (MCO) a member is enrolled in, such as Banner University Family Care, Mercy Care, or UnitedHealthcare Community Plan. Some MCO formularies do include generic amlodipine at no cost-share; others require a prior authorization or substitute a different first-line calcium channel blocker.

Members enrolled in AHCCCS Complete Care should check their plan's 2026 formulary document directly at the Arizona Health Care Cost Containment System website or call 1-800-654-8713. If your MCO excludes amlodipine, your prescriber can request a formulary exception or therapeutic substitution to a covered calcium channel blocker. Alternatively, because the cash price runs about $8 per month, some patients choose to pay out of pocket rather than manage a prior authorization process.

The JNC 8 guideline, published in JAMA, recommends a thiazide diuretic, calcium channel blocker, ACE inhibitor, or ARB as initial pharmacologic treatment for hypertension in the general non-Black adult population [4]. This guideline support means prescribers have a strong clinical basis to request formulary exceptions for amlodipine when preferred agents are not tolerated.

Clinical outcome data back that position. The ASCOT-BPLA trial (N=19,257) compared an amlodipine-based regimen with an atenolol-based regimen in patients with hypertension and at least three additional cardiovascular risk factors. Amlodipine reduced fatal and non-fatal stroke by 23% (P<0.0001) and all-cause mortality by 11% compared with atenolol at a median follow-up of 5.5 years [5]. Prescribers citing ASCOT-BPLA often succeed in prior authorization appeals when an MCO requires documentation of clinical rationale.

Commercial Insurance Coverage of Amlodipine in Arizona

Most commercial plans sold on the Arizona Health Insurance Marketplace and through large employers cover generic amlodipine on Tier 1 (preferred generic), typically with a $0, $10 copay. Plans through Blue Cross Blue Shield of Arizona, Cigna, Aetna, and UnitedHealthcare generally place the generic on their lowest cost tier.

A 2023 JAMA Internal Medicine analysis of formulary data found that generic antihypertensives, including amlodipine, were covered on Tier 1 in over 90% of ACA marketplace plans nationally [6]. Arizona plans follow a similar pattern. If your plan places amlodipine on Tier 2 or higher, request a tier exception using the ASCOT-BPLA outcome data as clinical justification.

Medicare Part D coverage varies by plan. The Low Income Subsidy (Extra Help) program through the Social Security Administration can reduce the copay for amlodipine to $0, $4 for qualifying Arizona beneficiaries [7]. Standard Part D plans typically cover generic amlodipine at the $0, $5 preferred tier level. Patients enrolled in a Medicare Advantage plan sold in Arizona should verify their 2026 Evidence of Coverage document for the exact cost-share.

The FDA's Orange Book confirms that multiple generic manufacturers hold Paragraph IV certifications for amlodipine besylate tablets, ensuring continued generic competition and stable low pricing [1]. That competitive market pressure is the primary structural reason why Tier 1 placement is so common across Arizona commercial plans.

Compounded Amlodipine in Arizona: Legality and Practicality

Compounded amlodipine is legal in Arizona when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription from a licensed prescriber. Section 503A of the Federal Food, Drug, and Cosmetic Act governs these pharmacies; they are not required to register with the FDA as outsourcing facilities and operate under state board oversight [8].

Arizona's pharmacy practice act, administered by the Arizona State Board of Pharmacy, permits 503A compounding of commercially available drugs when a prescriber documents a clinical reason, such as a patient requiring a dose strength not commercially available (for example, 1 mg or 3 mg) or a liquid formulation for a patient who cannot swallow tablets [9]. Compounding a dose that replicates a commercially available product without documented medical necessity can create legal and regulatory exposure for the compounding pharmacy.

The practical cost angle is notable. Some telehealth platforms and compounding pharmacies that serve Arizona patients offer subscription-based hypertension management programs where compounded amlodipine (in non-commercially available strengths or formulations) is included at low or no additional cost as part of a bundled monthly fee. This has led to the "$0/month" figure circulating in the Arizona market. Patients should confirm that the prescribing platform uses a licensed Arizona prescriber, the compounding pharmacy holds an active Arizona 503A license, and the compound is prepared for a patient-specific clinical indication, not simply to reduce cost on a commercially available strength.

The framework below helps Arizona patients decide which pricing channel fits their situation:

1. Generic at retail (GoodRx or Walmart $4 program): best for uninsured or underinsured patients who need standard 2.5 mg, 5 mg, or 10 mg tablets.
2. Commercial insurance Tier 1: best for patients with employer-sponsored or ACA marketplace coverage; verify 2026 formulary before filling.
3. AHCCCS MCO formulary: check your specific plan; request prior authorization with ASCOT-BPLA citation if denied.
4. Medicare Part D or Extra Help: best for patients 65+ or those receiving Social Security Disability; verify plan-specific 2026 Evidence of Coverage.
5. Telehealth bundled with 503A compounding: appropriate when a non-standard dose or formulation is clinically indicated and documented; confirm licensure of prescriber and pharmacy.

The Evidence Base Behind Amlodipine Pricing and Value

Price alone does not determine value in antihypertensive therapy. The clinical evidence supporting amlodipine is extensive and directly relevant to why payers and prescribers continue to choose it over newer, costlier agents.

ASCOT-BPLA (Lancet, 2005) enrolled 19,257 hypertensive patients across the UK and Ireland and randomized them to amlodipine 5 to 10 mg plus perindopril 4 to 8 mg or atenolol 50 to 100 mg plus bendroflumethiazide 1.25 to 2.5 mg. The trial was stopped early at a median 5.5 years because of significant benefit in the amlodipine arm: 23% relative risk reduction in fatal and non-fatal stroke (P<0.0001), 24% reduction in cardiovascular events and procedures (P<0.0001), and 11% reduction in all-cause mortality (P=0.0247) [5]. These results, published in The Lancet, remain among the strongest outcome data for any antihypertensive agent.

The ACCOMPLISH trial (N=11,462) compared benazepril plus amlodipine versus benazepril plus hydrochlorothiazide in high-risk hypertensive patients and found that the amlodipine combination reduced the primary composite outcome of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 19.6% (P<0.001) [10]. That trial, published in the New England Journal of Medicine, further cemented amlodipine-based regimens in major hypertension guidelines.

The 2018 ACC/AHA Hypertension Guideline states: "For most patients requiring combination antihypertensive therapy, a RAAS inhibitor combined with a long-acting dihydropyridine CCB is preferred" [11]. Amlodipine is the most widely prescribed long-acting dihydropyridine CCB in the United States, and its appearance in that recommendation language reflects decades of outcome data.

A Cochrane systematic review of amlodipine for hypertension identified consistent blood pressure reductions of approximately 8/5 mmHg at 5 mg and 12/7 mmHg at 10 mg compared with placebo, with the most common adverse effect being dose-dependent peripheral edema affecting 4 to 9% of patients [12]. That edema rate is one clinical reason a prescriber might document medical necessity for a compounded lower dose (such as 2.5 mg or 1 mg) not readily available commercially.

A 2022 analysis in JAMA Cardiology examined adherence patterns among patients prescribed once-daily versus twice-daily antihypertensives and found that once-daily agents including amlodipine had a 12-month adherence rate of 72% versus 58% for twice-daily regimens (P<0.001), reinforcing the practical value of amlodipine's pharmacokinetic profile [13].

Telehealth Prescribing of Amlodipine in Arizona

Arizona law permits telehealth prescribing of amlodipine. The state amended its telemedicine statute (A.R.S. § 36-3602) to allow a valid prescriber-patient relationship to be established via synchronous audio-visual technology, meaning a licensed Arizona physician, NP, or PA can evaluate your blood pressure history and prescribe amlodipine without an in-person visit [14].

The Arizona Medical Board and the Arizona Board of Osteopathic Examiners both confirm that prescribing controlled and non-controlled medications via telehealth is permitted when the clinical encounter meets standard-of-care documentation requirements. Amlodipine is not a controlled substance, which removes the DEA Ryan Haight Act barrier that applies to medications like buprenorphine.

Patients using telehealth platforms for hypertension management in Arizona should confirm that the prescriber holds an active Arizona license (searchable at the Arizona Medical Board website), that the pharmacy receiving the electronic prescription is licensed in Arizona, and that blood pressure monitoring data (home cuff readings, wearable data) is documented in the clinical record. The CDC reports that only about 1 in 4 American adults with hypertension have their condition under adequate control, and telehealth access to affordable generic agents like amlodipine is one evidence-supported mechanism for improving that rate [15].

A telehealth encounter typically costs $40, $75 for a first hypertension consultation on platforms serving Arizona. Combined with an $8/month generic prescription, a patient's first year of amlodipine therapy via telehealth runs approximately $170, $235 all-in, compared with $200, $400 for a traditional in-person cardiology or primary care visit plus pharmacy fill at list price.

Arizona Discount Programs and Savings Cards for Amlodipine

Several programs reduce amlodipine costs further for Arizona residents beyond the baseline generic price.

GoodRx and Blink Health. Free discount cards and app-based coupons available statewide. GoodRx consistently shows prices of $4, $7 for 30 tablets of generic amlodipine 5 mg at CVS, Walgreens, Fry's (Kroger), Walmart, and Safeway in Arizona. These coupons cannot be combined with insurance but are useful for uninsured patients or those in a deductible phase [16].

NeedyMeds. The NeedyMeds database lists patient assistance programs for Norvasc (brand amlodipine) through Pfizer's patient assistance program, which provides free brand medication to qualifying low-income patients in Arizona who do not qualify for Medicaid [17]. Income thresholds for the Pfizer program typically fall at or below 400% of the federal poverty level.

RxAssist. Aggregates pharmaceutical manufacturer assistance programs. Arizona patients can use RxAssist.org to identify current enrollment requirements for Pfizer's program and submit applications through their prescriber's office.

Arizona Health Care Cost Containment System (AHCCCS) Family Planning. For patients enrolled in AHCCCS Family Planning-only coverage, amlodipine is typically not within scope. Full-benefit AHCCCS members should check the 2026 preferred drug list at their specific MCO.

340B Program. Federally qualified health centers (FQHCs) operating in Arizona, including those in rural counties like Navajo, Apache, and Yuma, can dispense amlodipine at 340B pricing, which is frequently $1, $3 for a 30-day supply. Patients who receive care at an FQHC or qualifying hospital outpatient department may access this pricing without additional enrollment steps [18].

Side Effects and Clinical Considerations That Affect Cost Decisions

Understanding why a prescriber might select amlodipine over another agent, or choose a compounded dose, clarifies several cost-related decisions.

Peripheral edema is the most common reason patients discontinue amlodipine. It occurs in roughly 4 to 9% of patients at 5 mg and up to 15% at 10 mg, based on FDA prescribing information data [1]. Combining amlodipine with an ACE inhibitor or ARB reduces edema incidence because RAS inhibition counteracts the amlodipine-induced precapillary vasodilation that drives fluid shifts. ACCOMPLISH trial data support this combination both for edema reduction and for superior cardiovascular outcomes [10].

When edema forces discontinuation, the prescriber may trial a lower dose (2.5 mg), which is commercially available, or a dose between 2.5 mg and 5 mg (such as 3.75 mg), which requires compounding. That clinical scenario represents a legitimate 503A compounding indication in Arizona.

Grapefruit juice inhibits CYP3A4 and can increase amlodipine plasma concentrations by up to 40%, per a study published in Clinical Pharmacology and Therapeutics [19]. Patients taking amlodipine should be counseled to avoid large quantities of grapefruit or grapefruit juice, a counseling point that costs nothing but may prevent unnecessary dose escalation and associated higher pharmacy costs.

Drug interactions with simvastatin are worth noting for cost purposes. The FDA issued a safety communication recommending that the simvastatin dose not exceed 20 mg/day when co-administered with amlodipine, due to a modest increase in simvastatin exposure [20]. Patients taking higher-dose simvastatin may need to switch to rosuvastatin or pravastatin, which carries its own formulary and cost implications on Arizona insurance plans.